NCT03913559 2026-02-12
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
Korea University Guro Hospital
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
SWOG Cancer Research Network
Sanofi
University of Edinburgh
Milton S. Hershey Medical Center
Stanford University